home / stock / eras / eras quote
Last: | $2.06 |
---|---|
Change Percent: | 0.0% |
Open: | $2.42 |
Close: | $2.06 |
High: | $2.588 |
Low: | $2.03 |
Volume: | 1,900,302 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.06 | $2.42 | $2.06 | $2.588 | $2.03 | 1,900,302 | 03-29-2024 |
$2.06 | $2.42 | $2.06 | $2.588 | $2.03 | 1,900,231 | 03-28-2024 |
$2.06 | $1.99 | $2.06 | $2.08 | $1.96 | 289,482 | 03-27-2024 |
$1.98 | $2.1 | $1.98 | $2.13 | $1.98 | 325,028 | 03-26-2024 |
$2.07 | $2.21 | $2.07 | $2.22 | $2.06 | 339,910 | 03-25-2024 |
$2.15 | $2.15 | $2.15 | $2.18 | $2.13 | 466,388 | 03-22-2024 |
$2.15 | $2.17 | $2.15 | $2.19 | $2.08 | 455,780 | 03-21-2024 |
$2.1 | $2.11 | $2.1 | $2.11 | $1.99 | 311,125 | 03-20-2024 |
$2.05 | $2.03 | $2.05 | $2.105 | $2.03 | 369,301 | 03-19-2024 |
$2.05 | $2.21 | $2.05 | $2.24 | $2.05 | 459,345 | 03-18-2024 |
$2.14 | $2.06 | $2.14 | $2.195 | $2.06 | 852,824 | 03-15-2024 |
$2.08 | $2.19 | $2.08 | $2.2054 | $2.07 | 568,242 | 03-14-2024 |
$2.22 | $2.13 | $2.22 | $2.27 | $2.13 | 607,417 | 03-13-2024 |
$2.14 | $2.26 | $2.14 | $2.26 | $2.1 | 359,390 | 03-12-2024 |
$2.24 | $2.43 | $2.24 | $2.43 | $2.21 | 505,274 | 03-11-2024 |
$2.28 | $2.2 | $2.28 | $2.365 | $2.16 | 873,191 | 03-08-2024 |
$2.15 | $2.26 | $2.15 | $2.2771 | $2.15 | 596,739 | 03-07-2024 |
$2.22 | $2.28 | $2.22 | $2.295 | $2.16 | 638,195 | 03-06-2024 |
$2.27 | $2.35 | $2.27 | $2.37 | $2.24 | 761,465 | 03-05-2024 |
$2.35 | $2.58 | $2.35 | $2.58 | $2.29 | 976,245 | 03-04-2024 |
News, Short Squeeze, Breakout and More Instantly...
Erasca Inc. Company Name:
ERAS Stock Symbol:
NASDAQ Market:
SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS) ("Erasca"), a clinical-stage precision oncology company singularly focu...
SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS) (“Erasca”), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it h...
Gained global registrational clarity for naporafenib and achieved key clinical milestones for naporafenib, ERAS-007, and ERAS-801 Multiple data readouts expected in 2024 for naporafenib (SEACRAFT-1), ERAS-007 (HERKULES-3), and ERAS-801 (THUNDERBBOLT-1) and planned initiation of pivotal ...